As of Jan 17, 2025, Gilead Sciences, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $118.9. This suggests it may be undervalued by 29.4% compared to its current price of around $91.8, using a WACC of 6.7% and growth rates of 3.0%.
As of Jan 17, 2025, Gilead Sciences, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 6.7%.
As of Jan 17, 2025, Gilead Sciences, Inc.'s Enterprise Value (EV) is approximately $166.0B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.